TELA Bio Strengthens Board With Appointment Of Betty Jo Rocchio Following Departure Of Lisa Colleran

TELA Bio, Inc., a commercial-stage medical technology company focused on developing innovative solutions for soft-tissue reconstruction, has announced the appointment of Dr. Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors. The company also shared that Lisa Colleran, who has served on the Board for the past five years, has decided to step down.

Dr. Rocchio is a highly respected healthcare leader with extensive experience in advancing clinical practices, workforce innovation, and supply chain transformation across some of the nation’s largest healthcare systems. She was recently recognized as one of Modern Healthcare’s 50 Most Influential Clinical Executives. Currently, she serves as Executive Vice President and Chief Nurse Executive at Advocate Health, where she leads more than 42,000 nurses and oversees the nursing strategy across a six-state system. Her expertise spans clinical excellence, operations, and the integration of supply-chain strategies that enhance both patient care and cost efficiency.

Commenting on the appointment, Antony Koblish, Co-founder and Chief Executive Officer of TELA Bio, said, “We are thrilled to welcome Betty Jo to our Board of Directors. Her deep understanding of the group purchasing organization landscape and her proven ability to align clinical priorities with supply-chain innovation will be invaluable as we continue to strengthen our partnerships and drive value for our customers and shareholders.”

Expressing her enthusiasm about joining the Board, Dr. Rocchio said, “I am honored to be part of TELA Bio’s Board of Directors. Throughout my career, I’ve witnessed how collaboration between providers and group purchasing organizations can balance clinical excellence with financial sustainability. TELA Bio is uniquely positioned to deliver solutions that not only reduce costs but also improve patient outcomes. I look forward to contributing to this mission and supporting the company’s continued growth.”

Alongside this announcement, TELA Bio confirmed that Lisa Colleran will be stepping down from the Board after five years of service. Colleran, who currently serves as CEO of IC Surgical and previously held the role of CEO at LifeCell Corporation, has provided strategic guidance and commercial expertise since joining the Board in 2020. Her leadership has been instrumental in supporting TELA Bio’s business expansion, product development, and overall growth strategy.

“On behalf of the Board and the entire TELA Bio team, I want to thank Lisa for her outstanding contributions over the past five years,” said Koblish. “Her insights, experience, and commitment have played a significant role in helping us advance our strategic vision, expand our portfolio, and strengthen our commercial presence. We are deeply grateful for her service and wish her continued success in all her future endeavors.”